RVMD
HEALTHCARERevolution Medicines Inc
AI Insight
What's Moving RVMD Today?
No stock-specific AI insight has been generated for RVMD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.00$171.21
$169.51
Fundamentals
Market Cap$35.3B
P/E Ratio—
EPS$-7.11
Dividend Yield—
Dividend / Share—
ROE-76.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding212.6M
RVMD News
36 articles- Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic CancerYahoo Finance·Jun 23, 2026
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.Yahoo Finance·Jun 22, 2026
- Revolution Medicines (RVMD) Is Up 7.8% After Phase 3 Survival Data Validates RAS(ON) StrategySimply Wall Street·Jun 16, 2026
- Revolution Medicines (NASDAQ: RVMD) insider sale of 2,753 shares for $273,869.54Stock Titan·Jun 15, 2026
- Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to BuyYahoo Finance·Jun 13, 2026
- Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMDYahoo Finance·Jun 12, 2026
- Can Revolution Medicines Be a Game-Changer Stock?Motley Fool·Jun 11, 2026
- TNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsYahoo Finance·Jun 9, 2026
- Tango Therapeutics stock surges on pancreatic cancer trial dataQz·Jun 9, 2026
- Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer TreatmentYahoo Finance·Jun 8, 2026
- Tango Skyrockets On Eye-Popping Pancreatic Cancer ResultsYahoo Finance·Jun 8, 2026
- Top Midday GainersYahoo Finance·Jun 8, 2026
- Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and PatentsYahoo Finance·Jun 8, 2026
- Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?Yahoo Finance·Jun 8, 2026
- Tango data add to growing momentum for pancreatic cancer drugsBiopharmadive·Jun 8, 2026
- Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-BellYahoo Finance·Jun 8, 2026
- Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerYahoo Finance·Jun 8, 2026
- Total equity of Revolution Medicines, Inc. – XETR:42ZTradingView·Jun 7, 2026
- Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?Yahoo Finance·Jun 5, 2026
- GSK, Takeda and others notch key clinical wins in tough-to-treat diseasesPharmavoice·Jun 5, 2026
- Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.Motley Fool·Jun 5, 2026
- Redwood City company develops pill to treat pancreatic cancer, and trial results are promisingNBC Bay Area·Jun 5, 2026
- Assessing Revolution Medicines (RVMD) Valuation After Positive Daraxonrasib Phase 3 Results At ASCO 2026Yahoo Finance·Jun 4, 2026
- Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC SaysYahoo Finance·Jun 2, 2026
- Revolution Medicines, Inc. announced that it will highlight the groundbreaking results from the Phase 3 Rasolute 302 pivotal clinical trial of Daraxonrasib in previously treated patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.Bitget·May 31, 2026
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic CancerGlobeNewswire Inc.·May 31, 2026
- RVMD: Morgan Stanley Smith Barney lists 3,121 shares for sale (05/26/2026)Stock Titan·May 27, 2026
- Reassessing Revolution Medicines (RVMD) Valuation After Positive Phase 3 RASolute 302 Oncology ResultsSimply Wall Street·May 25, 2026
- What Revolution Medicines (RVMD)'s Phase 3 Daraxonrasib Survival Data Means For ShareholdersSimply Wall Street·May 24, 2026
- Eagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMDMarketBeat·May 21, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewswire Inc.·May 6, 2026
- SCHA vs. ISCB Comes Down to Sector Tilt and Your Drawdown ToleranceThe Motley Fool·Apr 25, 2026
- Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 19, 2026
- IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?Benzinga·Apr 19, 2026
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswire Inc.·Apr 15, 2026
- Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: AnalystBenzinga·Mar 25, 2026
All 36 articles loaded
Price Data
Open$163.30
Previous Close$169.51
Day High$171.25
Day Low$163.05
52 Week High$171.21
52 Week Low$34.00
52-Week Range
$34.00$171.21
$169.51
Fundamentals
Market Cap$35.3B
P/E Ratio—
EPS$-7.11
Dividend Yield—
Dividend / Share—
ROE-76.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding212.6M
About Revolution Medicines Inc
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—